Introduction To present a nationwide survey on the current attitudes towards stereotactic radiotherapy(SRT) combined with PARPi in oligometastatic/oligoprogressive/oligorecurrent ovarian cancer(oMPR-OC) patients.

Methods A 19-item questionnaire was developed by OC specialists and distributed online.

Results Respondents(100) were radiation oncologists (57%),medical oncologists (32%),and gynecologic oncologists (11%).54% of respondents considered the medical oncologist to be the primary oncologist for oMPR-OC,while 23% preferred the radiation oncologist and 15% favored the gynecologic oncologist.73% discuss the case in the multidisciplinary tumor board,while 15%,6%,and 2% sent the patients straight to SRT, surgery,or chemotherapy, respectively.In 2022,74% of the experts interviewed treated with SRT less than 10 oMPR-OC patients.Concomitant PARPi treatment was highly heterogeneous and subjective.Patients receiving both PARPi and SRT had little to no reported side effects.Although 69% of respondents feel there is a benefit to the combination, a significant variation in how PARPi is managed during SRT administration was found.Specifically,34% of experts do not interrupt the administration,while 52% pause and restart it later.43% of respondents believe that the PARPi dosage should not be reduced when administered concurrently with SRT.69% of respondents believe that SRT dose should not be decreased while receiving PARPi, if the constraints are met.The majority of respondents(40%) favoured the use of expert consensus for enhancing the oMPR-OCclinical management,while others(34%) suggested following clinical guidelines.

Conclusion/Implications This study reports a perceived lack of or low toxicity with the combination of PARPi and SRT,and a significant degree of heterogeneity concerning the clinical protocols for combining SRT with PARPi.Moreover, it emphasizes the low number of patients who have received this treatment approach nationwide.